RESUMEN
Controlling wildlife populations to mitigate human-wildlife conflicts and the spread of zoonotic diseases is an ever-growing necessity. The objective of this study was to evaluate a single-dose anti-gonadotropin-releasing hormone vaccine (GonaCon, USDA/NWRC, Fort Collins, CO, USA) as a non-lethal alternative for population control in free-ranging, synanthropic male capybara. In addition to infertility efficacy of this treatment, potential effects on the alpha male's secondary sexual characteristics and agonist behavior need to be assessed because any alterations in these factors could lead to population management failure. The treatment group (nâ¯=â¯3) received 1â¯mL of the anti-GnRH vaccine, intramuscularly, and the control group (nâ¯=â¯2) a 1â¯mL sham vaccine. Reproductive behavior and social group dynamics were monitored for 30 days prior to inoculation (June 2017) with continuous observations occurring during the study period. Antifertility effects were assessed by conducting exams of testicular morphology, semen characteristics, and histological analysis (after 270 days via hemi-gonadectomy). Compared to the control group, the testicles of the treated males had severe atrophy (Pâ¯<⯠0.05), oligozoospermia and greater numbers of sperm cells in a static developmental phase. Courtship and agonistic alpha male behavior were not altered, and the group's social integrity was maintained. Results indicate there was 100% infertility in capybara males, observed throughout the study period of 18 months, and equally important, the male's alpha characteristics were not affected by the treatment, which is imperative for successful capybara population control efforts.
Asunto(s)
Conducta Agonística , Anticoncepción Inmunológica/métodos , Anticonceptivos Masculinos/uso terapéutico , Roedores/fisiología , Conducta Sexual Animal , Vacunas Anticonceptivas/uso terapéutico , Conducta Agonística/efectos de los fármacos , Animales , Animales Salvajes , Anticoncepción Inmunológica/veterinaria , Anticonceptivos Masculinos/administración & dosificación , Relación Dosis-Respuesta a Droga , Femenino , Hormona Liberadora de Gonadotropina/antagonistas & inhibidores , Hormona Liberadora de Gonadotropina/inmunología , Masculino , Regulación de la Población/métodos , Reproducción/efectos de los fármacos , Roedores/inmunología , Análisis de Semen/veterinaria , Conducta Sexual Animal/efectos de los fármacos , Testículo/efectos de los fármacos , Potencia de la Vacuna , Vacunas Anticonceptivas/administración & dosificaciónRESUMEN
A sequence of studies is reviewed that reported the domestic horse (Equus caballus) mare as an appropriate and accessible research platform for recording clinical and laboratory data post-immunisation with anti- GnRH and -zona pellucida (ZP) immunocontraceptive vaccines. Experience with a native porcine ZP (pZP) vaccine in African elephant (Loxodonta africana) cows highlighted needs for improving vaccine formulations and more clearly defining associated ovarian effects and safety profiles. Initially, the efficacy, reversibility and safety of the GnRH vaccine Improvac® in mares was demonstrated using reproductive tract ultrasonography and concurrently measuring serum antibody titres and progesterone concentrations. Results informed the study design and minimally invasive monitoring of post-treatment ovarian steroid responses of this vaccine in free-ranging African elephant cows. A subsequent sequence of studies reported reversible contraceptive and immunological efficacy in pony mares immunised with pZP formulated with Freund's adjuvants. By comparison, mares treated with a recombinant ZP3 and ZP4 (reZP) vaccine showed disappointing responses. Unexpectedly, most pZP-treated mares showed ovarian inactivity. In attempting to understand this response, results showed the involvement of cytotoxic (CD8+) T-cells negatively correlated to serum ovarian steroid and anti-Müllerian hormone (AMH) levels. Of concern was the prevalence of injection-site lesions ascribable to Freund's adjuvants. Following this, mares treated with both pZP and a novel reZP vaccine formulated with non-Freund's adjuvants showed comparable immunological responses and ovarian inactivity, notably without adverse treatment reactions. In addition, measuring AMH showed promise for monitoring ovarian function in anti-ZP-treated animals.
Asunto(s)
Anticoncepción Inmunológica/veterinaria , Elefantes , Caballos , Vacunas Anticonceptivas/uso terapéutico , Animales , Investigación Biomédica/métodos , Investigación Biomédica/tendencias , Anticoncepción Inmunológica/métodos , Elefantes/inmunología , Femenino , Caballos/inmunología , Modelos Animales , Modelos Biológicos , Vacunas Anticonceptivas/inmunología , Medicina Veterinaria/métodos , Medicina Veterinaria/tendenciasRESUMEN
Wildlife and humans are increasingly competing for resources worldwide, and a diverse, innovative, and effective set of management tools is needed. Controlling abundance of wildlife species that are simultaneously protected, abundant, competitive for resources, and in conflict with some stakeholders but beloved by others, is a daunting challenge. Free-ranging horses (Equus caballus) present such a conundrum and managers struggle for effective tools for regulating their abundance. Controlling reproduction of female horses presents a potential alternative. During 2009-2017, we determined the long-term effectiveness of GnRH vaccine (GonaCon-Equine) both as a single immunization and subsequent reimmunization on reproduction and side effects in free-ranging horses. At a scheduled management roundup in 2009, we randomly assigned 57 adult mares to either a GonaCon-Equine treatment group (n = 29) or a saline control group (n = 28). In a second roundup in 2013, we administered a booster vaccination to these same mares. We used annual ground observations to estimate foaling proportions, social behaviors, body condition, and injection site reactions. We found this vaccine to be safe for pregnant females and neonates, with no overt deleterious behavioral side effects during the breeding season. The proportion of treated mares that foaled following a single vaccination was lower than that for control mares for the second (P = 0.03) and third (P = 0.08) post-treatment foaling seasons but was similar (P = 0.67) to untreated mares for the fourth season, demonstrating reversibility of the primary vaccine treatment. After two vaccinations, however, the proportion of females giving birth was lower (P <0.001) than that for control mares for three consecutive years and ranged from 0.0-0.16. The only detectable adverse side effect of vaccination was intramuscular swelling at the vaccination site. Regardless of vaccine treatment (primary/secondary), approximately 62% (34/55) of immunized mares revealed a visible reaction at the vaccine injection site. However, none of these mares displayed any evidence of lameness, altered gait or abnormal range of movement throughout the 8 years they were observed in this study. Our research suggests that practical application of this vaccine in feral horses will require an initial inoculation that may provide only modest suppression of fertility followed by reimmunization that together could result in greater reduction in population growth rates over time.
Asunto(s)
Anticoncepción Inmunológica , Efectividad Anticonceptiva , Hormona Liberadora de Gonadotropina/inmunología , Caballos , Inmunización Secundaria , Vacunas Anticonceptivas/uso terapéutico , Animales , Animales Salvajes , Anticoncepción Inmunológica/efectos adversos , Anticoncepción Inmunológica/métodos , Anticoncepción Inmunológica/veterinaria , Femenino , Caballos/inmunología , Inmunización Secundaria/efectos adversos , Inmunización Secundaria/métodos , Inmunización Secundaria/veterinaria , Embarazo , Distribución Aleatoria , Vacunación/efectos adversos , Vacunación/métodos , Vacunación/veterinariaRESUMEN
An important determinant in the selection of any contraceptive agent is the impact on ovarian function, both in the short and longer term. In this study, ovarian activity was monitored in mares immunised with one of the following vaccine formulations; native porcine zona pellucida (pZP), recombinant zona pellucida proteins ZP3 and ZP4 (reZP), pZP and reZP combined or a commercially available anti-GnRH vaccine. The ZP antigens were prepared in an adjuvant formulation consisting of 6% polymeric adjuvant (Montanide™ PetGel A, Seppic, France) and 500⯵g polyinosinic-polycytidylic acid - TLR3-agonist (Poly(I:C) HMW VacciGrade™, Invivogen, USA). A vehicle-only control group was administered the adjuvant formulation without antigen. Ovarian activity was monitored using clinical observations (transrectal palpation and ultrasonography of the reproductive tract) in addition to blood sampling for serum progesterone and anti-Müllerian hormone (AMH) concentrations while employing a low sampling frequency. Treatments and measurements were initiated in December (southern hemisphere summer) and subsequent data collection was performed in January, February, March and May. Both reZP and anti-GnRH vaccination were associated with clinically evident ovarian suppression in the short term. Ovarian activity in mares administered a reZP or anti-GnRH vaccine was significantly different to adjuvant control and pZP treated mares. Serum AMH concentrations were different between pZP and anti-GnRH treated mares 3.5 months after the final vaccination. Serum AMH concentrations were significantly correlated with mare age, serum progesterone and ovarian volume.
Asunto(s)
Anticoncepción Inmunológica/veterinaria , Hormona Liberadora de Gonadotropina/inmunología , Caballos , Ovario/efectos de los fármacos , Vacunas Anticonceptivas/uso terapéutico , Zona Pelúcida/inmunología , Animales , Hormona Antimülleriana/sangre , Quimioterapia Adyuvante , Femenino , Ovario/fisiología , PorcinosRESUMEN
BACKGROUND: Stray dogs are the reservoirs and carriers of rabies and are definitive hosts of echinococcosis. To control the overpopulation of stray dogs, zona pellucida 3 (ZP3), a primary receptor for sperm, is a potential antigen for developing contraceptive vaccines. To enhance the immune responses and contraceptive effects of canine ZP3 (cZP3), dog gonadotropin-releasing hormone (GnRH) and a T cell epitope of chicken ovalbumin (OVA) were selected to construct two fusion proteins with cZP3, ovalbumin-GnRH-ZP3 (OGZ) and ovalbumin-ZP3 (OZ), and their contraceptive effects were evaluated in mice. METHODS: The synthesized DNA sequences of OGZ and OZ were cloned into plasmid pET-28a respectively. The fusion proteins OGZ and OZ were identified by SDS-PAGE and Western blot. Mice were immunized with OGZ, OZ and cZP3, and the infertility rates were monitored. Mice immunized with mouse ZP3 (mZP3) or adjuvant alone were used as positive control and negative control, respectively. cZP3- and GnRH-specific antibodies (Abs) were detected by ELISA. The bindings of the Abs to oocytes were detected by indirect immunofluorescence assay. The paraffin sections of mice ovaries were observed under microscope for analyzing pathological characteristics. RESULTS: SDS-PAGE and Western blot analyses showed that the two fusion proteins OGZ and OZ were correctly expressed. ELISA results showed that OGZ vaccine induced both cZP3- and GnRH-specific Abs, and OZ vaccine induced cZP3-specific Ab, which lasted for up to 168 days. The levels of follicle stimulating hormone (FSH) and estradiol (E2) in sera were significantly decreased in OGZ immunized mice. Indirect immunofluorescence results showed that Abs induced by cZP3 and mZP3 could bind to the mouse ZP and dog ZP each other. Compared with the adjuvant group, all vaccine immunized groups significantly decreased the fertility rate and mean litter size. Interestingly, the fertility rate in OGZ-immunized group is the lowest, and only 1 mouse out of 10 mice is fertile. Histological analysis of murine ovarian sections indicated that most of the infertile mice in the immunized groups lacked mature follicles as well as accompanied by inflammatory infiltration. Meanwhile, immunization with OGZ decreased the number of corpora lutea in the infertile mice. CONCLUSIONS: The fusion protein OGZ resulted in the lowest fertility rate and the least mean litter size in the immunized mice. OGZ might be a promising antigen for developing a new contraceptive vaccine for stray dog controlling.
Asunto(s)
Anticoncepción Inmunológica/métodos , Perros , Ratones , Modelos Animales , Vacunas Anticonceptivas/uso terapéutico , Glicoproteínas de la Zona Pelúcida/inmunología , Adyuvantes Inmunológicos , Animales , Anticoncepción Inmunológica/veterinaria , Evaluación Preclínica de Medicamentos , Femenino , Masculino , Ratones Endogámicos BALB C , Embarazo , Proteínas Recombinantes de Fusión/química , Proteínas Recombinantes de Fusión/inmunologíaRESUMEN
An alternative to surgical sterilization for fertility control of animals (wild, zoo, farm, and domestic) is needed to prevent problems related to overpopulation, including culling and relocation. A PubMed and Google Scholar database search was conducted using the keywords 'contraceptive vaccine animals,' 'immunocontraception animals,' 'non-surgical sterilization animals,' 'PZP vaccine,' and 'GnRH vaccine.' The searches from 1972 to 2015 yielded over 1500 publications. These articles were read, and 375 were selected for detailed analysis. Articles referenced in these publications were also thoroughly examined. PZP and GnRH contraceptive vaccines (CVs) have been extensively investigated for fertility control of wild, zoo, farm, and domestic animal populations. Both vaccines have shown tremendous success with PZP vaccines taking the lead. Novel technologies and targets are being developed to improve existing vaccines and generate second-generation CVs. Single-shot vaccines, which can be delivered remotely, will greatly advance the field of immunocontraception for animal use with potential human application.
Asunto(s)
Anticoncepción Inmunológica/métodos , Anticoncepción Inmunológica/tendencias , Vacunas Anticonceptivas/uso terapéutico , Animales , Humanos , Vacunas Anticonceptivas/inmunologíaRESUMEN
Antibodies against GnRF elicited by vaccination with Improvac are expected to have the same effects on the gonads of female pigs as those observed in males and thus suppress estrus. The objective of this study was to evaluate whether a 3- or a 4-dose regimen of Improvac was effective in inducing and maintaining suppression of estrus in intact Iberian female pigs through 14 months of age. Sixty 18-week-old gilts were randomly assigned to one of the following three treatment groups: control (PBS injected), V3 (3-dose Improvac regimen), and V4 (4-dose Improvac regimen). Animals were tested for the presence of standing estrus in the presence of a boar three times per week until study completion at 60 weeks of age. Blood samples were regularly collected to determine the serum levels of anti-GnRF antibodies and progesterone. The weight and size of the uterus and the weight and activity of the ovaries were assessed at the time of euthanasia. For both treatment groups V3 and V4, a large reduction in the incidence of standing estrus was observed when compared to the control group (P < 0.0001). No significant differences between the V3 and V4 groups were observed. Both V3 and V4 groups had higher serum anti-GnRF antibody levels than the control group from 28 days after the first vaccination until the end of the study. In addition, both V3 and V4 groups had lower levels of progesterone than the control group from Day 112 until the end of the study (P < 0.0001 in all cases). Mean ovary weights at study end in treatment groups V3 and V4 were significantly lower (P < 0.0001) than those for the control group and not significantly different between the V3 and V4 groups. An onset of immunity of 2 weeks after the second vaccination and a long-lasting immunity of at least 20 weeks after the third vaccination were observed. In summary, both the 3-and 4-dose Improvac regimens were efficacious in reducing the incidence of standing estrus, serum progesterone levels, and the development of the uterus and ovaries.
Asunto(s)
Estro/efectos de los fármacos , Hormona Liberadora de Gonadotropina/inmunología , Porcinos/fisiología , Útero/efectos de los fármacos , Vacunación/veterinaria , Vacunas Anticonceptivas/uso terapéutico , Animales , Anticuerpos/sangre , Femenino , Tamaño de los Órganos/efectos de los fármacos , Progesterona/sangre , Útero/patologíaRESUMEN
Contraceptive vaccines have been proposed for controlling the growing human population and wildlife population management. Multiple targets such as gonadotropin releasing hormone (GnRH), luteinizing hormone, follicle stimulating hormone, gonadotropin receptors, sperm-specific proteins and zona pellucida glycoproteins have been exploited to develop contraceptive vaccine and their efficacy investigated and shown in various experimental animal models. Vaccines based on GnRH have found application in immuno-castration of male pigs for prevention of boar-taint. Vaccines based on zona pellucida glycoproteins have shown promising results for population management of wild horses and white-tailed deer. Phase II clinical trials in women with ß-human chorionic gonadotropin (ß-hCG)-based contraceptive vaccine established proof of principle that these can be developed for human application. Block in fertility by ß-hCG contraceptive vaccine was reversible. Further research inputs are required to establish the safety of contraceptive vaccines, improve their immunogenicity and to develop novel vaccine delivery platforms for providing long lasting immunity.
Asunto(s)
Descubrimiento de Drogas/métodos , Descubrimiento de Drogas/tendencias , Vacunación/estadística & datos numéricos , Vacunas Anticonceptivas/aislamiento & purificación , Vacunas Anticonceptivas/uso terapéutico , Animales , Ensayos Clínicos Fase II como Asunto , Humanos , Medicina Veterinaria/métodosRESUMEN
This study investigated the effects of Improvac and Bopriva, two anti-GnRF immunization products, on testicular function in boars. We predicted that both products would diminish testicular function; however, we specifically tested the hypothesis that the duration of efficacy for Bopriva would be longer than that of Improvac. Animals were immunized with either Improvac or Bopriva and then observed ten weeks after the second injection. Serum GnRF antibody titers rose after the second injection and peaked approximately two weeks later. At the same time testosterone concentrations decreased to undetectable levels and remained below assay detection for at least six weeks. At approximately eight weeks, testosterone began to increase in animals treated with Improvac though levels remained decreased in Bopriva treated animals throughout the ten weeks. Daily sperm production at 10 weeks was significantly reduced in both treatment groups; however, the reduction was greater in Bopriva treated boars. Examination of testes of both treatments revealed incomplete spermatogenesis with impaired spermatid production and reduced seminiferous tubule diameter. These findings were universal in Bopriva treated animals, but Improvac treated animals exhibited morphologies intermediate between Bopriva treated animals and control boars. Overall testicular function in Bopriva boars remained suppressed ten weeks post-immunization while Improvac boars appeared to be recovering.
Asunto(s)
Anticuerpos/farmacología , Hormona Liberadora de Gonadotropina/inmunología , Inmunización/veterinaria , Porcinos/fisiología , Testículo/efectos de los fármacos , Vacunas Anticonceptivas/farmacología , Vacunas Sintéticas/farmacología , Androsterona/metabolismo , Animales , Anticuerpos/uso terapéutico , Masculino , Semen/efectos de los fármacos , Semen/metabolismo , Maduración Sexual/efectos de los fármacos , Maduración Sexual/fisiología , Escatol/metabolismo , Recuento de Espermatozoides/veterinaria , Espermatogénesis/efectos de los fármacos , Espermatogénesis/fisiología , Testículo/fisiología , Factores de Tiempo , Vacunas Anticonceptivas/uso terapéutico , Vacunas Sintéticas/uso terapéuticoRESUMEN
The producer of vaccine against GnRH recommends that immunocastrated pigs are to be slaughtered within 4 to 6 weeks after the second vaccination (V2). The objective of the study was to examine the effect of shorter or longer delay on steroid hormones, boar taint compounds, and morphologic and histologic traits of reproductive organs. Forty male pigs (individually housed and fed a commercial diet) were assigned within litter to four treatment groups, 10 pigs were left entire (EM27) and the others were vaccinated against GnRH (Improvac, Pfizer Animal Health) at the age of 12 and 19 weeks. Pigs were slaughtered at 21 (IC21), 24 (IC24), and 27 (IC27 and EM27) weeks of age. Two EM27 pigs died during the experiment, one IC21 pig was excluded because of illness, one IC27 pig was a nonresponder, and two pigs (IC24 and IC27) were hermaphrodites. To assess the effect on steroid hormones, blood was taken at 12, 15, 19, 21, and 24 weeks of age. Subcutaneous fat and reproductive organs were sampled after slaughter for determination of androstenone, skatole, morphologic, and histologic measurements. Immmunocastration interrupted the rise of estrogen and caused a substantial fall of testosterone in IC21, IC24, and IC27 pigs. As a result, androstenone and skatole levels were successfully reduced regardless of the time elapsed from V2. The weight of the reproductive organs was also drastically reduced, the shrinkage being proportional to the length of the interval between V2 and slaughter and was the most evident for vesicular glands, followed by bulbourethral glands, and testes. Corresponding changes were observed also on a histologic level with a progressive decrease in the size and number of Leydig cells, a diminishing immunoreactivity of 3ß-hydroxysteroid dehydrogenase/Δ-5-4 isomerase, and luteinizing hormone receptor, along with a shrinkage of tubuli seminiferi, atrophy of seminiferous epithelium, and a loss of germ cells, indicating a disruption in testicular spermatogenetic function. Regression of the glandular tissue with a decreasing amount of secreta was also observed for bulbourethral and vesicular glands. The investigated physiologic, morphologic, and histologic traits were progressive with the increasing delay to slaughter (clearly seen already 2 weeks after V2), though no signs of functional or morphological restoration was observed within 8 weeks after V2.
Asunto(s)
Mataderos , Castración , Anticoncepción Inmunológica/veterinaria , Genitales/citología , Hormonas Esteroides Gonadales/análisis , Escatol/análisis , Porcinos/metabolismo , Androstenos/análisis , Androstenos/metabolismo , Animales , Castración/métodos , Castración/veterinaria , Anticoncepción Inmunológica/métodos , Genitales/metabolismo , Hormonas Esteroides Gonadales/metabolismo , Hormona Liberadora de Gonadotropina/inmunología , Masculino , Maduración Sexual/fisiología , Escatol/metabolismo , Porcinos/fisiología , Factores de Tiempo , Vacunas Anticonceptivas/farmacología , Vacunas Anticonceptivas/uso terapéuticoRESUMEN
Because of overpopulation of African elephants in South Africa and the consequent threat to biodiversity, the need for a method of population control has become evident. In this regard, the potential use of the porcine zona pellucida (pZP) vaccine as an effective means for population control is explored. While potential effects of pZP treatment on social behavior of African elephants have been investigated, no examination of the influence of pZP vaccination on the endocrine correlates in treated females has been undertaken. In this study, ovarian activity of free-ranging, pZP-treated African elephant females was monitored noninvasively for 1 yr at Thornybush Private Nature Reserve, South Africa, by measuring fecal 5α-pregnan-3ß-ol-20-on concentrations via enzyme immunoassay. A total of 719 fecal samples from 19 individuals were collected over the study period, averaging 38 samples collected per individual (minimum, maximum: 16, 52). Simultaneously, behavioral observations were made to record the occurrence of estrous behavior for comparison. Each elephant under study showed 5α-pregnan-3ß-ol-20-on concentrations rising above baseline at some period during the study indicating luteal activity. Average 5α-pregnan-3ß-ol-20-on concentrations were 1.61 ± 0.46 µg/g (mean ± SD). Within sampled females, 42.9% exhibited estrous cycles within the range reported for captive African elephants, 14.3% had irregular cycles, and 42.9% did not appear to be cycling. Average estrous cycle duration was 14.72 ± 0.85 wk. Estrous behavior coincided with the onset of the luteal phase and a subsequent rise in 5α-pregnan-3ß-ol-20-on concentrations. Average 5α-pregnan-3ß-ol-20-on levels positively correlated with rainfall. No association between average individual 5α-pregnan-3ß-ol-20-on concentrations or cyclicity status with age or parity were detected. Earlier determination of efficacy was established via fecal hormone analysis with no pregnancies determined 22 mo post-treatment and onward. Results indicate the presence of ovarian activity amongst pZP-treated female African elephants in 2 yr after initial immunization. Further study should now be aimed toward investigating the long-term effects of pZP vaccination on the reproductive function of female African elephants.
Asunto(s)
Elefantes , Heces/química , Pregnanos/análisis , Vacunas Anticonceptivas/uso terapéutico , Zona Pelúcida/inmunología , Animales , Animales Salvajes , Conducta Animal/fisiología , Elefantes/inmunología , Elefantes/metabolismo , Elefantes/fisiología , Ciclo Estral/metabolismo , Ciclo Estral/fisiología , Femenino , Fase Luteínica/metabolismo , Masculino , Concentración Osmolar , Regulación de la Población/métodos , Pregnanos/metabolismo , Sudáfrica , PorcinosRESUMEN
The population explosion and unintended pregnancies resulting in elective abortions continue to impose major public health issues. This calls for a better method of contraception. Immunocontraception has been proposed as a valuable alternative that can fulfill most, if not all, of the properties of an ideal contraceptive. There are several targets that are being explored for contraceptive vaccine development. Leukemia inhibitory factor (LIF), a member of interleukin-6 family, is required for embryo development and successful blastocyst implantation in several mammalian species. The present study was conducted to examine if LIF can be a target for the development of a birth control vaccine. Three sequences from LIF and two sequences from LIF-receptor (LIF-R) that span the regions involved in ligand-receptor binding were delineated, and peptides were synthesized based upon these sequences. Antibodies raised against these five peptides reduced LIF bioactivity in an in vitro culture assay using BA/F3 mLIF-R-mpg130 cells. Vaccines were prepared by conjugating these peptides to various carrier proteins. Immunization of female mice with these peptide vaccines induced a long-lasting, circulating as well as local antibody response in various parts of the genital tract, and resulted in a significant (P ≤ 0.05) inhibition in fertility in all the three trials; the LIF-R peptide vaccines proved to be a better vaccine target. The data indicate that LIF/LIF-R is an excellent target for the development of a birth control vaccine. This is the first study, to our knowledge, that examined LIF/LIF-R as a target for immunocontraception. The findings of this study can be easily translated to humans since LIF/LIF-R is also important for implantation and pregnancy in women.
Asunto(s)
Anticoncepción Inmunológica/métodos , Factor Inhibidor de Leucemia/antagonistas & inhibidores , Factor Inhibidor de Leucemia/inmunología , Vacunas Anticonceptivas/uso terapéutico , Animales , Anticuerpos/administración & dosificación , Anticuerpos/efectos adversos , Anticuerpos/farmacología , Anticuerpos/uso terapéutico , Formación de Anticuerpos/efectos de los fármacos , Formación de Anticuerpos/fisiología , Células Cultivadas , Anticoncepción/efectos adversos , Anticoncepción/métodos , Anticoncepción Inmunológica/efectos adversos , Implantación del Embrión/efectos de los fármacos , Implantación del Embrión/inmunología , Femenino , Fertilidad/efectos de los fármacos , Fertilidad/inmunología , Masculino , Ratones , Ratones Endogámicos BALB C , Fragmentos de Péptidos/síntesis química , Fragmentos de Péptidos/inmunología , Embarazo , Conejos , Vacunas Anticonceptivas/administración & dosificación , Vacunas Anticonceptivas/efectos adversos , Vacunas Anticonceptivas/farmacologíaRESUMEN
It has become increasingly recognized that polymer particle size can have a profound effect on the interactions of particle-based vaccines with antigen presenting cells (APCs) thereby influencing and modulating ensuing immune responses. With the aim of developing chitosan particle-based immunocontraceptive vaccines, we have compared the use of chitosan-based nanoparticles and chitosan-based microparticles as vaccine delivery vehicles for vaccine candidates based on luteinizing hormone-releasing hormone (LHRH). Particles, functionalized with chloroacetyl groups, which allows the covalent attachment of thiol-containing antigens, were able to adsorb ~60-70% of their weight of peptide-based antigen and 10-20% of their weight of protein-based antigen. Quantitation by amino acid analysis of antigen associated with particles demonstrated a correlation between associated antigen and the degree of chloracetylation of particles. Visualization of fluorescently labeled antigen-loaded particles by confocal microscopy indicated that the majority of antigen was localized at the particle surface with a smaller amount located in the interior. We also found that uptake of both fluoresceinated nanoparticles and microparticles by dendritic cells occurred in a manner dependent on particle concentration. Nanoparticles trafficked from the injection site to draining lymph nodes faster than microparticles; high numbers of nanoparticle-bearing cells appeared in draining lymph nodes on day 3 and microparticles on day 4. This difference in trafficking rate did not, however, appear to have any significant impact on the ensuing immune response because inoculation with both peptide-conjugated and protein-conjugated particles induced high levels of LHRH-specific antibodies. In the case of protein-conjugated particles, the levels of antibodies elicited were similar to those elicited following inoculation with antigen emulsified with complete Freund's adjuvant. The approach to vaccine design that we have described here could represent another useful method for inducing immune responses against microbial, viral and tumorigenic protein antigens.
Asunto(s)
Quitosano/química , Portadores de Fármacos/administración & dosificación , Hormona Liberadora de Gonadotropina/administración & dosificación , Nanopartículas/química , Fragmentos de Péptidos/administración & dosificación , Vacunas Anticonceptivas/administración & dosificación , Acetatos/química , Acetilación/efectos de los fármacos , Anhídridos/química , Animales , Células Cultivadas , Quitosano/metabolismo , Células Dendríticas/citología , Células Dendríticas/inmunología , Células Dendríticas/metabolismo , Portadores de Fármacos/metabolismo , Portadores de Fármacos/farmacocinética , Portadores de Fármacos/uso terapéutico , Composición de Medicamentos , Femenino , Hormona Liberadora de Gonadotropina/antagonistas & inhibidores , Hormona Liberadora de Gonadotropina/farmacocinética , Hormona Liberadora de Gonadotropina/uso terapéutico , Halogenación/efectos de los fármacos , Inmunidad Activa , Ganglios Linfáticos/inmunología , Ganglios Linfáticos/metabolismo , Ratones , Ratones Endogámicos BALB C , Microesferas , Nanopartículas/ultraestructura , Tamaño de la Partícula , Fragmentos de Péptidos/antagonistas & inhibidores , Fragmentos de Péptidos/farmacocinética , Fragmentos de Péptidos/uso terapéutico , Propiedades de Superficie , Distribución Tisular , Vacunas Anticonceptivas/metabolismo , Vacunas Anticonceptivas/farmacocinética , Vacunas Anticonceptivas/uso terapéuticoRESUMEN
This is a review of current status and future perspectives on the development of antisperm contraceptive vaccines (CV) and immunocontraceptives. The development of antisperm CV is an exciting proposition. There is a strong rationale and recent data indicating that this proposition can translate into reality. The search for novel sperm-specific antigens/genes, that can be used for CV, continues using various recent developing technologies. Various approaches of proteomics, genomics, reproductive biology, mucosal immunity and vaccinology and several novel technologies such as gene knockout technology, phage display technology, antibody engineering, differential display technique, subtractive hybridization, and hybridoma technology are being used to delineate sperm-specific antigens and construct CV. Various sperm antigens/genes have been delineated, cloned, and sequenced from various laboratories. Vaccination with these sperm antigens (recombinant/synthetic peptide/DNA) causes a reversible contraceptive effect in females and males of various animal species, by inducing a systemic and local antisperm antibody response. The efficacy is enhanced by combination vaccination, including peptides based on various sperm antigens. Several human novel scFv antibodies with unique complementarity-determining regions (CDRs), that react with specific well-defined fertility-related sperm antigens, have been synthesized. These human infertility-related antibodies may find application in the development of novel immunocontraceptives. Besides finding the novel sperm antigens, the present and future focus is on enhancing the immunogenicity, bioefficacy, and on obliterating the inter-individual variability of the immune response, and proceeding for primate and human clinical trials. Multi-epitope vaccines combining sperm proteins involved in various steps of fertilization cascade have been found to enhance the immunogenicity and bioefficacy of the contraceptive effect. The in vitro synthesis of infertility-related human scFv antibodies may provide unique once-a-month immunocontraceptives, the first of its kind, for human use. The multi-epitope CV and preformed engineered human antibodies of defined specificity may obliterate the concern related to inter-individual variability of the immune response.
Asunto(s)
Anticoncepción Inmunológica/métodos , Anticonceptivos/inmunología , Regulación de la Población/métodos , Espermatozoides/inmunología , Vacunas Anticonceptivas/inmunología , Vacunas Sintéticas/inmunología , Animales , Antígenos/inmunología , Clonación Molecular , Regiones Determinantes de Complementariedad/inmunología , Anticoncepción Inmunológica/tendencias , Femenino , Fertilidad/efectos de los fármacos , Fertilidad/inmunología , Humanos , Masculino , Ratones , Regulación de la Población/tendencias , Proteínas Recombinantes/química , Proteínas Recombinantes/genética , Anticuerpos de Cadena Única/inmunología , Vacunas Anticonceptivas/uso terapéutico , Vacunas Sintéticas/uso terapéuticoRESUMEN
Current methods of contraception lack specificity and are accompanied with serious side effects. A more specific method of contraception is needed. Contraceptive vaccines can provide most, if not all, the desired characteristics of an ideal contraceptive. This article reviews several factors involved in the establishment of pregnancy, focusing on those that are essential for successful implantation. Factors that are both essential and pregnancy-specific can provide potential targets for contraception. Using database search, 76 factors (cytokines/chemokines/growth factors/others) were identified that are involved in various steps of the establishment of pregnancy. Among these factors, three, namely chorionic gonadotropin (CG), leukemia inhibitory factor (LIF), and pre-implantation factor (PIF), are found to be unique and exciting molecules. Human CG is a well-known pregnancy-specific protein that has undergone phase I and phase II clinical trials, in women, as a contraceptive vaccine with encouraging results. LIF and PIF are pregnancy-specific and essential for successful implantation. These molecules are intriguing and may provide viable targets for immunocontraception. A multiepitope vaccine combining factors/antigens involved in various steps of the fertilization cascade and pregnancy establishment may provide a highly immunogenic and efficacious modality for contraception in humans.
Asunto(s)
Gonadotropina Coriónica/inmunología , Anticoncepción Inmunológica/métodos , Implantación del Embrión/inmunología , Servicios de Planificación Familiar/métodos , Fertilización/inmunología , Factor Inhibidor de Leucemia/inmunología , Vacunas Anticonceptivas/inmunología , Antígenos/inmunología , Ensayos Clínicos como Asunto , Anticonceptivos/inmunología , Citocinas/inmunología , Bases de Datos Genéticas , Implantación del Embrión/efectos de los fármacos , Epítopos/inmunología , Femenino , Fertilización/efectos de los fármacos , Humanos , Masculino , Embarazo , Proteínas Recombinantes/inmunología , Espermatozoides/inmunología , Vacunas Anticonceptivas/uso terapéuticoRESUMEN
The year 2011 marks the 84th year of the discovery of human chorionic gonadotropin (hCG) by Ascheim and Zondek. Originally considered and employed as a reliable diagnostic index for pregnancy, the multiple roles of hCG as an initiator and sustainer of pregnancy are now recognized. Besides pregnancy, the expression of hCG or its subunits is observed in a number of cancers of diverse type, in particular at advanced stage. Cancers expressing hCG/subunits have poor prognosis and adverse survival. Thus, immunological approaches against hCG have applications for control of fertility and for treatment of terminal cancers. Various mechanisms by which hCG exercises its action are discussed. These include its role as autocrine growth promoter, inhibitor of apoptosis, promotor of angiogenesis, invasiveness, and protection against rejection by the immune system. The article reviews various vaccines developed for control of fertility and for therapy of advanced-stage cancers expressing ectopically hCG/subunits. Also reviewed are the recombinant fully humanized and chimeric antibodies usable for emergency contraception, as vacation contraceptive, and as therapeutic antibodies for treatment of cancers.
Asunto(s)
Anticuerpos/uso terapéutico , Vacunas contra el Cáncer/inmunología , Gonadotropina Coriónica/antagonistas & inhibidores , Gonadotropina Coriónica/inmunología , Neoplasias/tratamiento farmacológico , Subunidades de Proteína/antagonistas & inhibidores , Subunidades de Proteína/inmunología , Vacunas Anticonceptivas/inmunología , Vacunas Sintéticas/inmunología , Anticuerpos/inmunología , Apoptosis/efectos de los fármacos , Vacunas contra el Cáncer/uso terapéutico , Línea Celular Tumoral , Gonadotropina Coriónica/genética , Gonadotropina Coriónica/metabolismo , Anticoncepción Inmunológica/métodos , Femenino , Fertilidad/efectos de los fármacos , Fertilidad/inmunología , Humanos , Inmunización Pasiva/métodos , Inmunoconjugados/uso terapéutico , Modelos Moleculares , Invasividad Neoplásica/inmunología , Invasividad Neoplásica/prevención & control , Neoplasias/inmunología , Neoplasias/patología , Neovascularización Patológica/tratamiento farmacológico , Embarazo , Subunidades de Proteína/genética , Subunidades de Proteína/metabolismo , Vacunas Anticonceptivas/uso terapéutico , Vacunas Sintéticas/uso terapéuticoRESUMEN
This manuscript provides an overview of past wildlife contraception efforts and discusses the current state of research. Two fertility control agents, an avian reproductive inhibitor containing the active ingredient nicarbazin and an immunocontraceptive vaccine, have received regulatory approval with the Environmental Protection Agency and are commercially available in the USA. OvoControl G Contraceptive Bait for Canada Geese and Ovo Control for pigeons are delivered as oral baits. An injectable immunocontraceptive vaccine (GonaCon Immunocontraceptive Vaccine) was registered with the Environmental Protection Agency for use in female white-tailed deer in September 2009. An injectable product (GonaCon Immunocontraceptive Vaccine) is registered for use in female white-tailed deer. Both products are labeled for use in urban/suburban areas where these species are overabundant. Several other compounds are currently being tested for use in wildlife in the USA, Europe, Australia and New Zealand that could have promise in the future. The development and use of reproductive inhibitors for resolving human-wildlife conflicts will depend on a number of factors, including meeting the requirements of regulatory agencies for use in the environment and on the biological and economical feasibility of their use. Use will also be dependent on health and safety issues and on public acceptance of the techniques.
Asunto(s)
Anticoncepción Inmunológica/veterinaria , Anticoncepción/veterinaria , Anticonceptivos/normas , Nicarbazina/uso terapéutico , Control de Plagas/métodos , Vacunas Anticonceptivas/uso terapéutico , Animales , Animales Salvajes , Aves , Anticoncepción Inmunológica/métodos , Ciervos , Hormona Liberadora de Gonadotropina/agonistas , Humanos , Nicarbazina/farmacología , América del Norte , Control de Plagas/legislación & jurisprudencia , Control de Plagas/estadística & datos numéricos , Opinión Pública , Vacunas Anticonceptivas/farmacologíaRESUMEN
Contraceptive vaccines (CV) may provide viable and valuable alternatives to the presently available methods of contraception. The molecules that are being explored for CV development either target gamete production [luteinizing hormone-releasing hormone (LHRH)/GnRH, FSH], gamete function [sperm antigens and oocyte zona pellucida (ZP)], and gamete outcome (HCG). CV targeting gamete production have shown varied degrees of efficacy; however, they either affect sex steroids causing impotency and/or show only a partial rather than a complete effect in inhibiting gametogenesis. However, vaccines based on LHRH/GnRH are being developed by several pharmaceutical companies as substitutes for castration of domestic pets, farm and wild animals, and for therapeutic anticancer purposes such as in prostatic hypertrophy and carcinoma. These vaccines may also find applications in clinical situations that require the inhibition of increased secretions of sex steroids, such as in uterine fibroids, polycystic ovary syndrome, endometriosis and precocious puberty. CV targeting molecules involved in gamete function such as sperm antigens and ZP proteins are exciting choices. Sperm constitute the most promising and exciting target for CV. Several sperm-specific antigens have been delineated in several laboratories and are being actively explored for CV development. Studies are focused on delineating appropriate sperm-specific epitopes, and increasing the immunogenicity (specifically in the local genital tract) and efficacy on the vaccines. Anti-sperm antibody (ASA)-mediated immunoinfertility provides a naturally occurring model to indicate how a vaccine might work in humans. Vaccines based on ZP proteins are quite efficacious in producing contraceptive effects, but may induce oophoritis, affecting sex steroids. They are being successfully tested to control feral populations of dogs, deer, horses and elephants, and populations of several species of zoo animals. The current research for human applicability is focused on delineating infertility-related epitopes (B-cell epitopes) from oophoritis-inducing epitopes (T-cell epitopes). Vaccines targeting gamete outcome primarily focus on the HCG molecule. The HCG vaccine is the first vaccine to undergo Phase I and II clinical trials in humans. Both efficacy and lack of immunopathology have been reasonably well demonstrated for this vaccine. At the present time, studies are focused on increasing the immunogenicity and efficacy of the birth control vaccine, and examining its clinical applications in various HCG-producing cancers. The present article will focus on the current status of the anti-sperm, anti-ZP, anti-LHRH/GnRH and anti-HCG vaccines.
Asunto(s)
Anticoncepción Inmunológica/métodos , Vacunas Anticonceptivas/uso terapéutico , Animales , Anticuerpos Monoclonales/química , Antígenos/química , Antineoplásicos/farmacología , Ensayos Clínicos como Asunto , Anticoncepción/métodos , Anticonceptivos/metabolismo , Anticonceptivos/uso terapéutico , Epítopos/química , Femenino , Fertilización , Hormona Liberadora de Gonadotropina/metabolismo , Hormonas/metabolismo , Humanos , Infertilidad/inmunología , Masculino , Mycobacterium tuberculosis/metabolismo , Oocitos/metabolismo , Péptidos/química , Neoplasias de la Próstata/terapia , Isoformas de Proteínas , Proteínas Recombinantes/química , Espermatozoides/metabolismo , Vacunas/uso terapéutico , Zona Pelúcida/metabolismoRESUMEN
The world's population is growing at a tremendous rate, affecting growth and development. Apart from this population growth, unintended pregnancies resulting in elective abortions continue to be a major public health issue. In over half of these unintended pregnancies, the women have used some type of contraception. Thus, there is an urgent need for a better method of contraception that is acceptable, effective and available. The contraceptive choices available to women at this time include steroid contraceptives, intrauterine devices, barrier methods, spermicides, natural family planning, male and female sterilisation, and recently available emergency contraceptives. Contraceptive vaccines (CVs) may provide viable and valuable alternatives that can fulfill most, if not all, properties of an ideal contraceptive. Since both the developed and most of the developing nations have an infrastructure for mass immunisation, the development of vaccines for contraception is an exciting proposition. The molecules that are being explored for CV development either target gamete production (gonadotropin releasing hormone, follicle-stimulating hormone and luteinising hormone), gamete function (zona pellucida [ZP] proteins and sperm antigens) or gamete outcome (human chorionic gonadotropin [hCG]). Disadvantages of CVs targeting gamete production are that they affect sex steroids and/or show only a partial effect in reducing fertility. CVs targeting gamete function are better choices. Vaccines based on ZP proteins are quite efficacious in producing contraceptive effects. However, they invariably induce oophoritis affecting sex steroids. Sperm antigens constitute the most promising and exciting targets for CVs. Several sperm-specific antigens have been delineated in several laboratories and are being actively explored for CV development. Antisperm antibody-mediated immunoinfertility provides a naturally occurring model to indicate how an antisperm vaccine will work in humans. Vaccines targeting gamete outcome primarily focus on the hCG molecule. The hCG vaccine is the first vaccine to undergo phase I and II clinical trials in humans. Both the efficacy and the lack of immunotoxicity have been reasonably well demonstrated for this vaccine. The present studies focus on increasing the immunogenicity and efficacy of this birth control vaccine.
Asunto(s)
Oogénesis/inmunología , Espermatogénesis/inmunología , Vacunas Anticonceptivas/uso terapéutico , Femenino , Humanos , Masculino , Oocitos/fisiología , Espermatozoides/fisiologíaRESUMEN
Vaccines have been used successfully to treat and eradicate infectious diseases; this has encouraged a major drive towards development of contraceptive vaccines (immunocontraception) as an additional method against rising human and animal populations. Despite three decades worth of research in this field, there are no licensed human contraceptive vaccines and less than ten for use in animals. The development of peptide antifertility vaccines has had a substantial impact on improving safety and specificity of immunogens, but has resulted in efficacy problems. Innovative strategies have been developed to overcome these problems.